Cancer breath test could soon be reality
The innovative new test, which uses an electronic nose to sniff-out cancer, has been developed by scientists and has gone through preliminary testing.
It was discovered that the Nano Artificial NOSE, also known as the Na-NOSE, could smell chemical signs of cancer in the breath of patients suffering from lung cancer and different types of head and neck cancer.
Published in the British Journal of Cancer, the results were based on a small study of 82 people. Out of the group, 22 people had lung cancer, 24 had a form of head or neck cancer and 36 were healthy.
The Na-Nose was able to tell the difference between the breath of participants with lung cancer, those with head and neck cancer and those that were healthy.
READ MORE FROM THE WDM CONTENT NETWORK:
TB screening is missing the majority of cases
A Twilight-style video is being used to advertise dentists
New pill developed to treat MS
Although it was only a preliminary trail, scientists are hopeful that it could provide a useful tool in detecting head and neck cancers which are often diagnosed late, and as a result more difficult to treat.
The results that came from the study were promising, although much larger studies need to be carried out to confirm them and to see if the Na-NOSE can differentiate between differnt types of head and neck cancer.
Dr Lesley Walker from Cancer Research UK said: “These interesting initial results show promise for the development of a breath test to detect head-and-neck cancers which are often diagnosed at an advanced stage.”
“But it's important to be clear that this is a small study, at a very early stage, so many more years of research with patients will be needed to see if a breath test could be used in the clinic.”
If it was found to be successful, the Na-NOSE could potentially be used to give an instant cancer diagnoses in doctor’s surgeries.
Lead researcher, Professor Hossam Haick, said: “There's an urgent need to develop new ways to detect head-and-neck cancer because diagnosis of the disease is complicated, requiring specialist examinations.”
“We've shown that a simple breath test can spot the patterns of molecules which are found in head-and-neck patients in a small, early study.”
“We now need to test these results in larger studies to find if this could lead to a potential screening method for the disease.”
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”